Examkin

Neurocognitive Disorders

65 questions

All types65Multiple choice34Matching14Ordering17
Question 61Question →

A 79-year-old hospitalized man with a history of mild vascular dementia develops acute-onset disorientation, visual hallucinations, and severe psychomotor agitation on his third evening following a laparoscopic cholecystectomy. He is shouting at the nursing staff, exhibiting a fluctuating level of consciousness, and repeatedly attempting to remove his peripheral intravenous catheter. Arrange the following management steps in the most appropriate clinical escalation sequence for treating this patient's acute behavioral disturbance.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence begins with non-pharmacological de-escalation and environmental optimization, followed by a medical evaluation for underlying triggers. If agitation persists and poses a severe safety risk, low-dose antipsychotics may be administered. Physical restraints are reserved as the absolute last resort.
The standard of care for acute delirium requires a stepwise escalation. First, ensure immediate safety through non-pharmacological means (sitters, reorientation). Second, identify the underlying cause (infection, hypoxia, pain). Third, use chemical restraints (antipsychotics) only if the patient remains a danger to themselves or others. Finally, utilize physical restraints strictly as a last resort, as they can worsen delirium and cause physical harm.

Step-by-Step Solution

1
Implement non-pharmacological interventions.
De-escalate the patient verbally, optimize lighting, and assign a bedside sitter.
This is the safest initial step that avoids the adverse effects of medications while addressing the patient's immediate behavioral symptoms.
2
Conduct a focused medical evaluation.
Check vital signs, assess for pain, review recent medications, and look for signs of infection or retention.
Delirium is a manifestation of an underlying physiological disturbance that must be identified and corrected to resolve the acute confusion.
3
Consider pharmacological intervention (chemical restraint).
Administer a low-dose antipsychotic (e.g., haloperidol).
This is only appropriate if the patient remains severely agitated despite non-pharmacological measures and is at risk of harming themselves or others.
4
Consider physical restraints.
Apply soft wrist restraints as a temporary measure.
This is strictly the last resort due to high risks of injury, paradoxically worsened agitation, and ethical concerns, used only to prevent immediate life-threatening events like removing a breathing tube or necessary IV lines.

Key Concept

Clinical escalation pathway for the management of acute delirium and agitation
Question 62Question →

A 68-year-old man is brought to the clinic by his son for evaluation of cognitive decline. The son reports that his father's memory has worsened significantly over the past 4 months, which coincided with the unexpected death of his wife. The patient frequently misplaces his glasses and forgets the names of acquaintances. During the interview, the patient appears visibly distressed about his memory, stating, "My brain is completely useless now. I can't remember a single thing." When asked orientation questions and to perform a three-word delayed recall, he frequently answers "I don't know" with little initial effort. However, with gentle encouragement and extra time, he is able to correctly recall two of the three words. The patient also reports early morning awakenings, poor appetite, and a 5-kg (11-lb) weight loss over the past 3 months. His medical history includes hypertension well-controlled on lisinopril. Vital signs are within normal limits. Physical and neurological examinations reveal no abnormalities. Which of the following is the most appropriate next step in management?

Show answer & explanation

Answer: Initiate trial of a selective serotonin reuptake inhibitor

Answer

Initiate trial of a selective serotonin reuptake inhibitor
The patient's clinical picture is classic for major depressive disorder with prominent cognitive impairment, a condition historically termed 'pseudodementia'. Key distinguishing features from a primary neurocognitive disorder (such as Alzheimer disease) include the relatively acute onset following a significant life stressor, the patient's severe distress and retained insight regarding his memory loss, and the characteristic 'I don't know' responses on cognitive testing that improve with encouragement. In true dementia, patients typically have an insidious onset, lack insight (anosognosia), try to conceal their deficits, and genuinely cannot recall information despite encouragement. The presence of vegetative symptoms (weight loss, early morning awakenings) further supports the diagnosis of major depression. The most appropriate next step is to initiate a trial of an antidepressant medication, such as an SSRI.

Step-by-Step Solution

1
Analyze the onset and nature of the cognitive symptoms.
The cognitive decline had an abrupt onset 4 months ago following a major stressor (spouse's death), and the patient shows significant distress and insight regarding his memory loss.
Differentiating between neurocognitive disorders and psychiatric conditions requires evaluating the timeline, precipitating factors, and the patient's awareness of their deficits.
2
Evaluate the patient's performance on cognitive testing.
The patient gives 'I don't know' answers and displays poor initial effort, but performs adequately with encouragement.
Patients with true dementia typically make genuine attempts to answer but confabulate or fail, whereas patients with depression often show poor effort but intact underlying cognition.
3
Identify the primary underlying pathology.
The combination of depressed mood, weight loss, early morning awakenings, and cognitive complaints points to major depressive disorder (pseudodementia).
Recognizing the somatic and psychological criteria for major depression is necessary to guide treatment.
4
Determine the most appropriate management.
Treating the underlying depression with a selective serotonin reuptake inhibitor (SSRI) is the correct next step.
Reversing the depressive episode will likely resolve the secondary cognitive impairment.

Key Concept

Major depressive disorder in the elderly can present with prominent cognitive deficits (pseudodementia), which are distinguished from true dementia by the patient's prominent distress over memory loss, poor effort on testing that improves with encouragement, and an acute onset associated with a stressor. The primary treatment is targeted at the underlying depression.
Question 63Question →

A 66-year-old retired accountant is evaluated in the clinic for a 12-month history of progressive memory impairment. His husband reports that the patient frequently forgets recent conversations, struggles to manage their household finances, and occasionally gets lost in familiar neighborhoods. His past medical history is significant for well-controlled hypertension and hyperlipidemia. Vital signs are within normal limits, and a general physical examination shows no acute abnormalities. The physician suspects a major neurocognitive disorder and plans a comprehensive diagnostic evaluation. Arrange the following diagnostic and evaluative steps in the most appropriate, standard chronological sequence for the workup of this patient.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The standard diagnostic sequence begins with objective cognitive screening, followed by laboratory evaluation for reversible causes, structural neuroimaging to assess for cerebrovascular or space-occupying lesions, and finally, advanced functional imaging or biomarker testing if the diagnosis remains unclear.
The evaluation of suspected major neurocognitive disorder is a standardized, step-wise process designed to minimize unnecessary testing while identifying reversible causes. It begins with establishing the presence and severity of cognitive decline using validated bedside screening tools. Once cognitive impairment is objectively confirmed, the next step is to rule out common, reversible metabolic and systemic causes using routine laboratory tests. Following this, structural neuroimaging (preferably an MRI) is obtained to rule out structural lesions (e.g., subdural hematoma, tumors) and cerebrovascular disease, as well as to identify supportive anatomical changes (e.g., hippocampal atrophy). Finally, if the diagnosis remains uncertain and differentiating between specific neurodegenerative diseases is necessary for management, advanced diagnostics such as FDG-PET or cerebrospinal fluid biomarkers are indicated.

Step-by-Step Solution

1
Confirm and quantify the cognitive impairment.
Administration of a standardized bedside cognitive assessment tool.
Provides an objective baseline and confirms the clinical suspicion of neurocognitive decline before pursuing expensive or invasive testing.
2
Screen for systemic, reversible causes of cognitive decline.
Routine laboratory testing (e.g., vitamin B12, thyroid-stimulating hormone).
Endocrine and metabolic derangements are common, easily treatable etiologies that must be ruled out early in the diagnostic pathway.
3
Evaluate for macroscopic intracranial pathology.
Structural neuroimaging (preferably magnetic resonance imaging).
Identifies occult strokes, tumors, and hydrocephalus, while providing supportive anatomical evidence (e.g., medial temporal lobe atrophy) for neurodegenerative conditions.
4
Differentiate ambiguous neurodegenerative syndromes.
Functional neuroimaging (e.g., FDG-PET) or biomarker analysis.
Utilized only when the initial standard clinical and structural workup is inconclusive, particularly to differentiate between Alzheimer disease and frontotemporal dementia.

Key Concept

Sequential Diagnostic Evaluation of Major Neurocognitive Disorders
Estimated Time:1m 15s
Question 64Question →

Match the following neurocognitive or related psychiatric conditions with their most appropriate initial pharmacological management strategy or critical therapeutic constraint.

Click a left item, then click its matching right item

Items

Dementia with Lewy bodies (DLB) presenting with distressing visual hallucinations
Behavioral variant frontotemporal dementia (bvFTD) presenting with severe impulsivity
Mild-to-moderate Alzheimer disease newly diagnosed in the outpatient setting
Major depressive disorder presenting with dementia-like cognitive impairment (pseudodementia)

Matches

Show answer & explanation

Answer

Dementia with Lewy bodies matches with neuroleptic sensitivity; Behavioral variant frontotemporal dementia matches with SSRI use for behaviors and avoiding cholinesterase inhibitors; Alzheimer disease matches with initiating acetylcholinesterase inhibitors; Pseudodementia matches with antidepressant therapy reversing cognitive deficits.
Each condition pairs with a unique and essential pharmacological principle: DLB requires avoiding typical antipsychotics, bvFTD relies on SSRIs while avoiding AChE inhibitors, Alzheimer disease is primarily treated with AChE inhibitors, and pseudodementia cognitive deficits are reversible with antidepressants.

Step-by-Step Solution

1
Analyze the management of Dementia with Lewy bodies.
Identify the critical contraindication of typical antipsychotics due to extreme neuroleptic sensitivity.
Exposure to typical antipsychotics in DLB can be fatal or cause severe, irreversible parkinsonism.
2
Evaluate treatments for behavioral variant frontotemporal dementia.
Select symptom-targeted management (SSRIs) and recognize that cognitive enhancers (donepezil) are ineffective and potentially harmful.
bvFTD involves frontal lobe atrophy affecting behavior; cholinergic deficits are not the primary pathophysiology, so AChE inhibitors can increase agitation.
3
Determine standard treatment for Alzheimer disease.
Select acetylcholinesterase inhibitors as the foundational initial therapy.
Alzheimer disease is characterized by a central cholinergic deficit, which is temporarily ameliorated by AChE inhibitors.
4
Identify the treatment goal for pseudodementia.
Select antidepressant therapy with the expectation of cognitive reversal.
The cognitive impairment in pseudodementia is secondary to major depressive disorder; treating the mood disorder resolves the cognitive deficits.

Key Concept

Pharmacological management and critical contraindications in major neurocognitive disorders
Question 65Question →

A 76-year-old man is evaluated in the clinic for progressive memory decline. Over the past 9 months, he has been increasingly forgetful, frequently misplacing household items, and recently became lost while driving home from his local grocery store. His son mentions that the patient's wife passed away 12 months ago; initially, the family attributed his forgetfulness to grief. The patient has a medical history of hypertension and bipolar I disorder, for which he has taken valproate for the past 25 years without any recent mood episodes. During the interview, the patient is cheerful, makes good eye contact, and attempts to joke away his memory lapses. When administered a cognitive assessment, he puts forth significant effort but scores 19/30, losing points on orientation, delayed recall, and intersecting pentagons. Which of the following is the most appropriate next step in management?

Show answer & explanation

Answer: Initiate donepezil therapy

Answer

Initiate donepezil therapy
The correct answer is initiating donepezil therapy. This patient presents with a classic progression of Alzheimer disease, characterized by an insidious onset of memory impairment (getting lost in familiar territory) and progressive cognitive decline over 9 months. A critical step in evaluating elderly patients with cognitive decline following a major life stressor (such as the loss of a spouse) is differentiating genuine major neurocognitive disorder from pseudodementia (major depressive disorder). Patients with genuine dementia often attempt to conceal their deficits (e.g., joking away memory lapses) and put forth significant effort on cognitive testing despite objectively failing. In contrast, patients with pseudodementia typically highlight their deficits, exert poor effort, and frequently answer questions with 'I don't know'. Because this patient has genuine dementia, initiating a cholinesterase inhibitor like donepezil is the most appropriate next step in management to help stabilize cognitive functioning.

Step-by-Step Solution

1
Evaluate the clinical presentation to differentiate between genuine major neurocognitive disorder (dementia) and major depressive disorder (pseudodementia).
The patient's insidious 9-month decline, getting lost in familiar places, attempts to conceal deficits through joking, and poor cognitive performance despite high effort strongly indicate genuine dementia.
Bereavement can cause depressive symptoms (pseudodementia) that mimic dementia, but pseudodementia typically presents with poor effort (frequent 'I don't know' answers) and highlighting of cognitive deficits.
2
Determine the appropriate initial management for the confirmed diagnosis.
The patient requires symptomatic treatment for Alzheimer disease.
Cholinesterase inhibitors such as donepezil are first-line pharmacological treatments to temporarily improve cognition and function in major neurocognitive disorders.

Key Concept

Differentiating genuine major neurocognitive disorder from pseudodementia based on clinical presentation and cognitive testing effort.
PreviousPage 4 / 4
Neurocognitive Disorders Practice Questions — USMLE Step 2 CK — Page 4 | Examkin